SL 651498

Drug Profile

SL 651498

Alternative Names: SL 65.1498

Latest Information Update: 18 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Anxiolytics; Indoles; Pyrrolidines; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 12 May 2003 A preclinical study has been added to the Anxiety disorders pharmacodynamics section
  • 23 Nov 2001 Phase-II clinical trials for Anxiety disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top